ArticleJournal of clinical medicine2024

Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.

Alicia López-Abad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.